The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / Making Pediatric Leukemia Testing Accessible
Oncology Omics Research and Innovations Precision medicine Molecular Pathology

Making Pediatric Leukemia Testing Accessible

Research into long-read transcriptome sequencing suggests single assays could close the molecular testing gap for pediatric patients

By Helen Bristow 11/18/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: Making Pediatric Leukemia Testing Accessible

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Making Pediatric Leukemia Testing Accessible
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPediatric leukemia; the interview discusses potential use in settings with limited diagnostic infrastructure.
Care SettingThe approach is under validation, including at the University of North Carolina and with international collaborators; concordance or non-inferiority with standard-of-care diagnostics remains to be assessed.

Key Highlights

  • Current pediatric leukemia testing may involve multiple time-consuming and expensive methods, including flow cytometry, karyotyping, FISH, and molecular tests.
  • The interview describes nanopore long-read sequencing as a lower-cost, portable platform for generating molecular data.
  • The reported workflow multiplexed up to 12 samples per flow cell, with estimated consumables costs of about $100 per case.
  • Computational tools were developed to support analysis without dedicated bioinformatics personnel.
  • Further validation is underway to assess concordance, or non-inferiority, with standard-of-care diagnostics.

Guideline-Based Recommendations

Diagnosis

  • The interview describes molecular classification as increasingly important for pediatric leukemia diagnosis, risk stratification, and treatment selection.
  • Long-read transcriptome sequencing is described as an approach under validation, not as an established replacement for standard diagnostics.

Management

  • The interview states that more precise, accurate molecular diagnostics could support assignment to targeted or risk-stratified therapy.

Monitoring & Follow-up

  • The researcher says validation is continuing at the University of North Carolina and with international collaborators.
  • The researcher identifies demonstrating concordance, or non-inferiority, with standard-of-care diagnostics as a next step.

Risks

  • The interview describes current testing as time-consuming and often expensive, requiring infrastructure, equipment, and expertise.
  • The researcher attributes worse pediatric leukemia outcomes in low- and middle-income countries in part to limited diagnostic capacity and specificity.

Patient & Prescribing Data

Children with leukemia; the approach is being explored for diagnostic settings with limited infrastructure, including low- and middle-income countries.

The interview suggests that molecular findings may inform targeted or risk-stratified therapy. It provides no prescribing regimens or patient-level treatment data.

Clinical Best Practices

    Related Resources & Content

      This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

      Newsletters

      Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

      Newsletter Signup Image

      About the Author(s)

      Helen Bristow

      Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

      More Articles by Helen Bristow

      Explore More in Pathology

      Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

      False

      Advertisement

      Recommended

      False

      Affiliations:

      Specialties:

      Areas of Expertise:

      Contributions:

      False

      The Pathologist
      Subscribe

      About

      • About Us
      • Work at Conexiant Europe
      • Terms and Conditions
      • Privacy Policy
      • Your Privacy Choices
      • Advertise With Us
      • Contact Us

      Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.